We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Puja P. Khanna, MD, MPH, of the University of Michigan, ...

Vyome Holdings, Inc. (Nasdaq: HIND) (“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today announced that the United States Patent and ...

† One patient had MMF as an initial treatment. ‡ In the study TAC and MMF were used alone or in combination. §In total, 17 patients were initially treated with MMF and steroids. ¶ Females represented ...

Please provide your email address to receive an email when new articles are posted on . Adding mycophenolate mofetil to a glucocorticoid in first-line treatment for immune thrombocytopenia improves ...

A drug currently used to prevent rejection in patients who receive solid organ transplants could have a use in the treatment of a completely different patient population ― those with immune ...

Myhibbin is expected to be commercially available in the second quarter of 2024. The Food and Drug Administration (FDA) has approved Myhibbin ™, a ready-to-use, oral suspension formulation of ...

Acute GVHD (aGVHD) remains a matter of concern after reduced intensity conditioning (RIC) allo-SCT, and its incidence might be expected to be higher when using allogeneic grafts from HLA-matched ...

Early use of mycophenolate mofetil in at-risk patients with SLE reduced the risk of severe flare, potentially delaying lupus nephritis. Early application of mycophenolate mofetil may reduce the ...

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, demonstrated that withholding mycophenolate mofetil for at least 10 days significantly ...

(HealthDay)—For adults with immune thrombocytopenia, the addition of mycophenolate mofetil to a glucocorticoid for first-line treatment is associated with fewer treatment failures and higher response ...

Credit: Azurity Pharmaceuticals. Myhibbin is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection. Myhibbin is expected to be commercially available in the second ...